DoubleChecks

What was claimed

Big Pharma has now woken up to the race for a cancer vaccine. We began the quest for personalized neoepitopes/mutations in 2015 at Nantomics; a decade of work is now coming to fruition and a vaccine cannot be created without that AI platform.

Our verdict

Needs caution

Multiple organizations have developed personalized cancer vaccines using various approaches. Peptide vaccines represent 64.8% of clinical trials, and companies like Moderna have advanced neoantigen vaccines. AI assists but is not strictly necessary for vaccine creation. While Nantomics did work on neoepitope vaccines, the broader field of neoepitope research predates 2015. Key research on mutation-specific T cells and tumor-specific mutant antigens was published in 2014, suggesting Nantomics was not the originator of this quest. (Only 1 of 3 AI systems responded.)

1 AI system respondedChecked Sep 7, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

A vaccine cannot be created without that AI platform

Incorrect95%
1 AI checked

We began the quest for personalized neoepitopes/mutations in 2015 at Nantomics

Misleading85%
1 AI checked

Big Pharma has now woken up to the race for a cancer vaccine

Can’t verify60%
1 AI checked

A decade of work is now coming to fruition

Verified80%
1 AI checked

Detailed Analysis

Did not respond

What other AI think

The statement contains partially accurate claims about Nantomics' work on neoepitope vaccines, but makes misleading absolute claims about necessity. The critical claim that "a vaccine cannot be created without that AI platform" is demonstrably false—multiple organizations have developed personalized cancer vaccines using different approaches. Additionally, neoepitope research predates the claimed 2015 start date.

Why this verdict

  • The statement contains partially accurate claims about Nantomics' work on neoepitope vaccines, but makes misleading absolute claims about necessity.
  • The critical claim that "a vaccine cannot be created without that AI platform" is demonstrably false—multiple organizations have developed personalized cancer vaccines using different approaches.
  • Additionally, neoepitope research predates the claimed 2015 start date.

Claims checked

A vaccine cannot be created without that AI platform

Incorrect95%
Multiple organizations have developed personalized cancer vaccines using various approaches. Peptide vaccines represent 64.8% of clinical trials, and companies like Moderna have advanced neoantigen vaccines. AI assists but is not strictly necessary for vaccine creation.

This claim may mislead readers without added context.

We began the quest for personalized neoepitopes/mutations in 2015 at Nantomics

Misleading85%
While Nantomics did work on neoepitope vaccines, the broader field of neoepitope research predates 2015. Key research on mutation-specific T cells and tumor-specific mutant antigens was published in 2014, suggesting Nantomics was not the originator of this quest.

This claim may mislead readers without added context.

Big Pharma has now woken up to the race for a cancer vaccine

Can’t verify60%
While evidence shows major companies like Moderna are conducting neoantigen vaccine trials, the vague claim about 'Big Pharma waking up' cannot be precisely verified without defining what constitutes sufficient industry engagement.
ChatGPTDid not respond

Share this result

Try DoubleChecks